Lumida
/TVTX
⌘K
Travere Therapeutics Inc

Travere Therapeutics Inc

TVTX
$56.71USD↑+2.59%+1.43 today

MARKET CAP

5.3B

P/E (TTM)

—

FWD P/E

36.1x

DAY RANGE

$53 – $57

52W RANGE

$15
$60

AI Summary

Stalk
Buy NowMedium

TVTX remains in a Stage 2 advancing phase with strong medium- and long-term uptrends. Active Higher Highs & Higher Lows and Lockout Rally patterns confirm demand-dominated continuation. Price is pulling back into the rising 9-EMA and 20-EMA zone, offering a favorable entry for continuation participation. Despite extreme overbought readings, Lockout Rally dynamics support further extension. Key risks include a breach of the EMA support zone and overhead resistance near recent highs.

  • ↑Q1 revenue $124.5M, up 88% YoY driven by Filspari adoption.
  • ↑Filspari sales of $105.2M with 993 new patient start forms.
  • ↓Net loss $37.1M in Q1 raises operational sustainability concerns.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company focused on developing innovative therapies for rare kidney diseases, notably IgA nephropathy and Focal Segmental Glomerulosclerosis (FSGS). The company targets unmet medical needs in this niche market and has positioned itself as a leader with its lead product, Filspari. With significant growth potential from expanding treatment indications and a robust pipeline, Travere is well-aligned with the increasing emphasis on specialized kidney therapies amidst evolving healthcare landscapes.

Bull says

  • ↑Q1 revenue $124.5M, up 88% YoY driven by Filspari adoption.
  • ↑Filspari sales of $105.2M with 993 new patient start forms.
  • ↑Potential $3B peak sales opportunity for Filspari in IgAN/FSGS.
  • ↑Anticipated FSGS approval could further boost revenue pipeline.
  • ↑Cash position $352M ensures sufficient operational runway through 2027.
  • ↑Strong growth momentum and favorable quality metrics support upside.

Bear says

  • ↓Net loss $37.1M in Q1 raises operational sustainability concerns.
  • ↓Negative earnings yield and weak profitability factors signal value risk.
  • ↓FDA review delays for FSGS approval could stall growth momentum.
  • ↓Intensifying competition from Novartis and Amgen may erode market share.
  • ↓Anticipated higher gross-to-net discounts could pressure revenue margins.
  • ↓Rising SG&A expenses risk margin compression if sales plateau.

Investment themes with TVTX

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 06-03-2026bullish

Transcript signals

Bull points

  • generated net product sales of $75.9 million in the first quarter, representing 90% growth over the same period last year, as well as continued sequential growth over last quarter.
  • maintained great momentum in the first quarter, generating $55.9 million in net product sales. We anticipate that we will have higher gross to net discounts for Filspari in 2025.
  • total revenue of $81.7 million reported for the first quarter of 2025. Of note, during the quarter, we sold drug product to our partner, CSLV, for as they continue their launch of Filspare in Europe. This activity accounted for $3.8 million of the license and collaboration revenue and a nearly proportional increase in cost of goods sold for the quarter.

Bear points

  • continue to anticipate more generic competition for Thiola and Thiola EC in the coming quarters, but we continue to be pleased with the performance thus far.
  • Total other income net for the first quarter of 2025 was $1.5 million, compared to $3.5 million in the same period of 2024. The difference is largely attributable to lower interest income during the period.
  • Net loss for the first quarter of 2025 was $41.2 million, or 47 cents per basic share, compared to $136.1 million, or $1.76 per basic share, for the same period in 2024.
Read full transcript analysis ›